Loading...
01/10 16:15
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report reveals significant revenue decline and ongoing net losses, with no immediate revenue boost expected from grants or partnerships. Despite reduced expenses, financial health remains weak. The Q&A section highlights uncertainties in clinical trials, regulatory approvals, and commercialization timelines, further dampening sentiment. Although operational efficiencies are noted, competitive pressures and economic uncertainties pose risks. Given these factors, a negative stock price reaction is anticipated over the next two weeks.
Total Revenue Decreased to $0.2 million in Q2 2025 compared to $2.7 million in Q2 2024. The decline was primarily due to the absence of grant revenue, which accounted for $2.5 million in the prior year period, while all revenue in Q2 2025 came from product sales.
Total Operating Expenses Decreased to $8.2 million in Q2 2025 from $10.1 million in Q2 2024. This reduction reflects efforts to improve operational efficiency.
Research and Development Expenses Decreased to $4.7 million in Q2 2025 from $5.6 million in Q2 2024, indicating a reduction in R&D spending year-over-year.
Net Loss Increased slightly to $7.7 million in Q2 2025 (loss of $0.23 per fully diluted share) compared to $7.6 million in Q2 2024 (loss of $0.25 per fully diluted share).
EBITDA Loss of $7.2 million in Q2 2025 compared to an adjusted EBITDA loss of $5.9 million in Q2 2024, reflecting a higher loss year-over-year.
Cash, Equivalents, and Marketable Investment Securities Ended Q2 2025 with $13.4 million, indicating the company's liquidity position.
Co-DX PCR platform: Steady advancements in the Co-DX PCR point-of-care platform. Clinical evaluations for all tests in the pipeline are on track for 2025. The platform includes tests for flu A and B, COVID, RSV, tuberculosis (TB), and an HPV 8-type multiplex panel.
Co-DX PCR COVID-19 test: Updated version undergoing clinical evaluation training. Plans to submit a 510(k) application to the FDA after evaluations. Expected market introduction in 2026.
TB test: Clinical evaluations to begin in India and South Africa by the end of 2025. Focus on increasing accessibility in high-need areas like India and Africa.
HPV 8-type multiplex panel: Clinical evaluations to start before year-end. Designed to detect 8 high-risk HPV subtypes and differentiate between HPV 16, 18, and 45. Supported by the Bill & Melinda Gates Foundation.
India and Africa market focus: Significant focus on India and Africa for TB and HPV tests. Joint venture with CoSara Diagnostics strengthens regulatory and manufacturing infrastructure in India.
Global commercialization strategy: Plans to leverage FDA 510(k) clearance for international commercialization. Focus on high-demand markets like the U.S. for respiratory panels.
Operational efficiencies: Operating expenses decreased to $8.2 million from $10.1 million YoY. R&D expenses reduced to $4.7 million from $5.6 million YoY.
Revenue and financials: Revenue decreased to $0.2 million from $2.7 million YoY. Net loss of $7.7 million compared to $7.6 million YoY. Ended Q2 with $13.4 million in cash and equivalents.
Regulatory and clinical milestones: Focused on achieving clinical evaluations and regulatory submissions for multiple tests in 2025.
Manufacturing expansion: Scaling manufacturing capacity in the U.S. and India to meet market demand upon platform launch.
Regulatory Approval Delays: The Co-Dx PCR testing platform and associated tests require regulatory approval and marketing authorization for diagnostic use, which are not yet obtained. Delays in these approvals could impact the company's ability to commercialize its products.
Revenue Decline: Total revenue for Q2 2025 decreased significantly to $0.2 million from $2.7 million in the prior year, indicating potential challenges in maintaining financial stability.
Net Loss: The company reported a net loss of $7.7 million for Q2 2025, slightly higher than the $7.6 million loss in the prior year, reflecting ongoing financial challenges.
Dependence on Grants: Revenue from grants has significantly decreased, with all revenue in Q2 2025 coming from product sales. This shift may create financial strain if product sales do not increase.
Market Competition: The company faces competitive pressures in the diagnostic testing market, particularly in the U.S. and international markets, which could impact its market share and profitability.
Supply Chain and Manufacturing Risks: The company relies on manufacturing facilities in South Salt Lake and India. Any disruptions in these facilities could delay production and commercialization.
Economic and Market Uncertainties: Economic conditions and market demand, particularly in target markets like India and Africa, could impact the adoption and sales of the company's diagnostic products.
Strategic Execution Risks: The company’s ability to meet its clinical evaluation, regulatory submission, and commercialization timelines is critical. Any delays or inefficiencies in these processes could adversely affect its strategic objectives.
Clinical Evaluations for Co-DX PCR Platform: The company remains on track to initiate clinical evaluations for all tests in its pipeline during 2025, including the Co-DX PCR COVID-19 test, flu A and B, COVID and RSV 4-plex respiratory panel, tuberculosis (TB) test, and HPV 8-type multiplex panel.
Regulatory Submissions and Approvals: Plans to submit a 510(k) application to the FDA for the updated COVID-19 test after clinical evaluations. Regulatory submissions for TB and HPV tests are anticipated in India and South Africa by the end of 2025.
Market Launch and Commercialization: The Co-DX PCR platform is expected to be introduced to the market in 2026, with a focus on point-of-care markets in the U.S., India, and Africa. The company is preparing for international commercialization following FDA clearance.
Tuberculosis (TB) Test: Clinical evaluations for the TB test are planned in India and South Africa before the end of 2025. The test aims to address high TB incidence in India and Africa, with manufacturing and distribution supported by CoSara Diagnostics.
HPV 8-Type Multiplex Panel: Clinical evaluations for the HPV test are expected to begin before the end of 2025, targeting regulatory submissions in India and South Africa. The test aims to improve global accessibility to HPV diagnostics.
ABCR 4-Plex Respiratory Panel: Clinical evaluations for the respiratory panel are expected to begin during the 2025 North American flu season. The test targets flu A and B, COVID-19, and RSV, with high domestic demand anticipated.
Manufacturing and Infrastructure Expansion: The company plans to expand manufacturing capacity in the U.S. and India to meet market demand upon platform launch.
Future Developments: The company aims to replicate its diagnostic platform for other infectious diseases and explore applications in veterinary, agricultural, and livestock sectors.
The selected topic was not discussed during the call.
The earnings call reveals significant concerns: declining revenue, net losses, and financial dependency on external funding. Despite improved operational efficiency, the company faces multiple risks, including regulatory and international expansion hurdles. The Q&A section highlights management's lack of clarity on strategic initiatives, such as CoSara's spinout, further contributing to uncertainty. While there are promising developments, like the affordable PCR Pro and strategic partnerships, the overall sentiment is negative due to financial performance and unresolved risks.
The earnings report reveals significant revenue decline and ongoing net losses, with no immediate revenue boost expected from grants or partnerships. Despite reduced expenses, financial health remains weak. The Q&A section highlights uncertainties in clinical trials, regulatory approvals, and commercialization timelines, further dampening sentiment. Although operational efficiencies are noted, competitive pressures and economic uncertainties pose risks. Given these factors, a negative stock price reaction is anticipated over the next two weeks.
The earnings call reveals several concerning factors: a significant revenue drop, net loss, and no shareholder return plan. Although operating expenses decreased, the lack of precise guidance on key product timelines and regulatory risks are troubling. The Q&A highlights management's vague responses, particularly on COVID test resubmission and pricing strategies. The absence of new partnerships or positive catalysts further dampens sentiment. Given these factors, and the company's small market cap, a negative stock reaction is anticipated.
The earnings call indicates significant challenges: a sharp revenue decline, net loss, and reliance on external funding. Despite cost management improvements, regulatory risks and competition remain high, with unclear timelines for key submissions. The Q&A session further highlights uncertainties, particularly around COVID test resubmissions and product launches. These factors suggest a negative sentiment, with potential stock decline in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
